VCEL vs. RGNX, ALEC, ITOS, CCCC, BDTX, QGEN, PCVX, RVMD, RGEN, and HALO
Should you be buying Vericel stock or one of its competitors? The main competitors of Vericel include REGENXBIO (RGNX), Alector (ALEC), iTeos Therapeutics (ITOS), C4 Therapeutics (CCCC), Black Diamond Therapeutics (BDTX), Qiagen (QGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), Repligen (RGEN), and Halozyme Therapeutics (HALO). These companies are all part of the "biological products, except diagnostic" industry.
Vericel (NASDAQ:VCEL) and REGENXBIO (NASDAQ:RGNX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and community ranking.
Vericel has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
Vericel has higher revenue and earnings than REGENXBIO. Vericel is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
Vericel has a net margin of 0.22% compared to REGENXBIO's net margin of -299.96%. Vericel's return on equity of 0.21% beat REGENXBIO's return on equity.
Vericel presently has a consensus target price of $51.33, indicating a potential downside of 1.89%. REGENXBIO has a consensus target price of $38.58, indicating a potential upside of 169.25%. Given REGENXBIO's higher probable upside, analysts plainly believe REGENXBIO is more favorable than Vericel.
REGENXBIO received 87 more outperform votes than Vericel when rated by MarketBeat users. Likewise, 65.64% of users gave REGENXBIO an outperform vote while only 61.86% of users gave Vericel an outperform vote.
88.1% of REGENXBIO shares are owned by institutional investors. 5.2% of Vericel shares are owned by insiders. Comparatively, 13.1% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Vericel had 7 more articles in the media than REGENXBIO. MarketBeat recorded 14 mentions for Vericel and 7 mentions for REGENXBIO. Vericel's average media sentiment score of 0.68 beat REGENXBIO's score of 0.43 indicating that Vericel is being referred to more favorably in the media.
Summary
Vericel beats REGENXBIO on 11 of the 18 factors compared between the two stocks.
Get Vericel News Delivered to You Automatically
Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
